Literature DB >> 21040312

Phthisis bulbi in retinoblastoma.

Seema Kashyap1, Rachna Meel, Neelam Pushker, Seema Sen, Sameer Bakhshi, Mandeep S Bajaj, Bhavna Chawla, Sumita Sethi, Supriyo Ghose, Mahesh Chandra.   

Abstract

BACKGROUND: Phthisis bulbi is a relatively uncommon and atypical clinical presentation of retinoblastoma.
DESIGN: Retrospective study conducted at a tertiary care hospital. PARTICIPANTS: Eighteen consecutive retinoblastoma patients with primary phthisis bulbi.
METHODS: Retrospective analysis of clinical, imaging and histopathological features of all retinoblastoma patients with primary phthisis bulbi, treated at our centre between January 2005 and December 2009. MAIN OUTCOME MEASURE: Clinical and histopathology features.
RESULTS: Eighteen (3.5%) retinoblastoma patients developed primary phthisis bulbi. The median age of presentation was 1.5 years. The median duration of symptoms before presentation was 6 months. In total, 15 out of 18 (83%) cases had bilateral disease. Among these, 80% (12/15) had advanced intraocular disease in the fellow eye. Most common first symptom was white reflex. History of orbital inflammation was present in 12/18 cases. Computed tomographic scan of orbit showed intraocular mass with calcific densities in 16 eyes. In two cases, hyperdense mass was seen without any calcification. On histopathology, residual viable tumour cells with characteristics of poorly differentiated retinoblastoma were found in 67% (12/18) eyes. High-risk factors were present in six cases with microscopic residual disease in three cases.
CONCLUSIONS: This is the largest case series of retinoblastoma patients with primary phthisis bulbi. Phthisis bulbi in retinoblastoma may be associated with bilateral disease in most cases and advanced intraocular disease in the fellow eye in a significant number of cases. Regression is incomplete in majority of these cases; therefore, enucleation must definitely be done in all cases of retinoblastoma presenting with phthisis bulbi.
© 2011 The Authors. Clinical and Experimental Ophthalmology © 2011 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21040312     DOI: 10.1111/j.1442-9071.2010.02426.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  6 in total

Review 1.  Retinoblastoma, the visible CNS tumor: A review.

Authors:  Helen Dimaras; Timothy W Corson
Journal:  J Neurosci Res       Date:  2018-01-03       Impact factor: 4.164

2.  A long follow-up of a patient with bilateral retinoblastoma who underwent globe-preserving therapy and had metastasis after 72mo.

Authors:  Yi Zhang; Dong-Sheng Huang; Wei-Ling Zhang; Yi-Zhuo Wang; Yan Zhou; Pin-Wei Zhang; Tao Han; Jian-Min Ma; Ji-Tong Shi; Xin Ge
Journal:  Int J Ophthalmol       Date:  2017-10-18       Impact factor: 1.779

3.  Pediatric Oculo-orbital Tumor Characteristics, Imaging and Histopathology Agreement in a Tertiary Level Teaching Hospital, Ethiopia.

Authors:  Semira Abrar Issa; Amal Saleh Nour; Getachew Assefa Neknek
Journal:  Ethiop J Health Sci       Date:  2022-03

4.  Retinoblastoma major review with updates on Middle East management protocols.

Authors:  Ihab Saad Othman
Journal:  Saudi J Ophthalmol       Date:  2012-04

5.  Distribution of phthisis bulbi and status of fellow eyes at a tertiary eye-care centre in Nigeria: a ten-year review.

Authors:  Bolajoko A Adewara; Sarat A Badmus; Olukemi T Olugbade; Edak Ezeanosike; Bernice O Adegbehingbe
Journal:  Afr Health Sci       Date:  2021-03       Impact factor: 0.927

6.  A case of retinoblastoma resulting in phthisis bulbi after proton beam radiation therapy.

Authors:  Norihiko Nakagawa; Takeshi Morimoto; Takako Miyamura; Shigenobu Suzuki; Hiroshi Shimojo; Kohji Nishida
Journal:  Am J Ophthalmol Case Rep       Date:  2022-09-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.